Overview:
HIV Antigen + Antibody Combo Rapid TestIntroduction: The HIV Antigen + Antibody Combo Rapid Test is a diagnostic tool designed to detect HIV antigen and antibody in serum, whole blood, or saliva samples, facilitating the screening of HIV infection. Caused by the human immunodeficiency virus transmitted via blood, sexual contact, or perinatal exposure, this viral infection presents with fever, weight loss, and severe complications like AIDS if untreated, particularly in high-risk populations. Per the 2023 Centers for Disease Control and Prevention guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in public health settings. This rapid diagnostic falls under virology and targets individuals with systemic symptoms or exposure risks, addressing the challenge of early detection to guide antiretroviral therapy. With morbidity rates elevated due to chronic progression, the test supports public health efforts by enabling early identification, facilitating management, and reducing transmission. Its multi-sample capability enhances its utility.
Other Names: HIV Combo Rapid Test.
FDA Status: FDA approved, CLIA certified for virology, compliant with 2025 standards.
Historical Milestone: Introduced in the 2000s by Abbott, this test advanced HIV detection, providing a rapid alternative to ELISA with antigen and antibody detection.
Purpose: The test screens for HIV antigen and antibody to guide infection diagnosis, assess immune status, and inform treatment and prevention strategies.
Test Parameters: Presence of HIV Antigen and Antibody, detected with reasonable specificity to indicate acute or chronic infection, typically detectable in serum or blood within 2-12 weeks of exposure.
Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report fever, weight loss, or recent risk behavior.
Specimen: Serum 2-5 mL, Whole Blood 2-5 mL, Saliva 1-2 mL, collected using sterile SST or EDTA tubes/containers, transported within 24 hours to maintain sample viability.
Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen and antibody integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not recommended, as freezing may degrade antigens and antibodies, increasing the risk of false negatives and compromising diagnostic accuracy.
Medical History: Patients should provide details on fever, weight loss, opportunistic infections, or prior HIV exposure, as well as any risk behavior or recent testing.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including AIDS, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.
Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or early sampling before seroconversion can affect results. Correlation with HIV RNA or clinical evaluation is recommended to confirm findings.
Clinical Significance: A positive result indicates possible HIV infection, necessitating further investigation like HIV RNA or infectious disease consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled too early.
Specialist Consultation: Infectious disease specialists or HIV specialists should be consulted for case management, treatment planning, and coordination with public health authorities.
Additional Supporting Tests: HIV RNA, CD4 count, or Western blot for confirmation.
Test Limitations: The test may produce false negatives in early infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes molecular methods.
References: CDC Guidelines 2023, Journal of Virology 2024, Infectious Diseases 2025.
